FDA and representatives of the generic drug industry meet quarterly to discuss topics related to the implementation of GDUFA. Minutes from these meetings are posted here. The January 15 meeting discussed ANDA labeling and included a review of action items and future planning.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
